Navigation Links
Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum
Date:10/24/2008

Conference will be held October 29-31 at the Palace Hotel, San Francisco

NEW YORK, Oct. 24 /PRNewswire/ -- Gerson Lehrman Group, the world's marketplace for expertise, and the Biotechnology Industry Organization (BIO) have set the scientific agenda for the Seventh Annual BIO Investor Forum. Featured therapeutic panels will include some of Gerson Lehrman Group's leading physician consultants along with executives from public and private equity biotechnology companies to discuss:

-- Congestive Heart Failure

-- Cystic Fibrosis

-- Epilepsy

-- Fibromyalgia

-- Lung Cancer

-- Neurodegenerative Diseases

-- Novel Solid Tumor Targets

-- Osteoporosis

-- Pre-ASH Primer

"With the financial markets experiencing an unprecedented level of volatility, investment professionals place a greater premium than ever before on sophisticated expertise to guide their decision-making," said Alexander Saint-Amand, President and Chief Executive Officer of Gerson Lehrman Group. "In the healthcare and biotechnology sectors, highly focused and unbiased education plays a critical role; the BIO Investor Forum brings together the three populations relevant to fully understand how to maneuver in this market: industry executives, sophisticated investors, and the world's top clinical thought leaders."

Through this partnership, BIO tapped Gerson Lehrman Group's network of more than 200,000 experts from around the world to identify clinicians and researchers to serve as panel speakers during the conference. The speakers were specifically identified to focus on some of the most interesting and novel development areas within the biotechnology industry, and represent some of the top clinical minds in their respective fields.

"This year's panel topics focus on disease areas in which we expect innovative new therapies to produce significant clinical advances, representing attractive investment and partnering opportunities," said Jim Greenwood, President and Chief Executive Officer of BIO. "Working with Gerson Lehrman Group allows BIO to provide the independent scientific and clinical expertise to offer outstanding Therapeutic Workshop panels for our investor and emerging company attendees."

The Seventh Annual BIO Investor Forum is a national investor conference featuring leading private and emerging public companies. The meeting attracts sophisticated healthcare venture and private equity investors, buy-side investors and research analysts. In addition, the Seventh Annual BIO Investor Forum draws business development executives from leading global pharmaceutical and mature biotechnology companies.

To see the latest updates to 2008 programming and speakers for the Seventh Annual BIO Investor Forum, please visit http://investorforum.bio.org/bif/2008/TW.html.

About Gerson Lehrman Group

Gerson Lehrman Group provides technology and services to support a marketplace for expertise. Since 1998, its platform for consultation and collaboration has helped the world's leading financial services firms, consultancies, corporations, and nonprofits find, engage, and manage experts in a broad range of industries and disciplines. Gerson Lehrman Group's unparalleled network of the world's leading expert consultants, known as the Gerson Lehrman Group Councils, includes more than 200,000 subject-matter experts who educate and provide insight to decision makers through a wide range of consulting methods, including telephone consultations, expert surveys, and seminars. Gerson Lehrman Group has invested in one of the world's most sophisticated infrastructures for expert recruiting and compliance. For more information about Gerson Lehrman Group, please visit http://www.glgroup.com.

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Gerson Lehrman Group and the Gerson Lehrman Group logo are registered trademarks of Gerson Lehrman Group [in the United States and other countries]. Failure to list any other Gerson Lehrman Group trademarks does not constitute a waiver of any rights to any Gerson Lehrman Group trademarks, including unregistered trademarks. Other names included in this press release may also be the registered or unregistered trademarks of their respective owners.

Gerson Lehrman Group Contact:

Christopher Stella

212-880-6517

Biotechnology Industry Organization Contact:

John Craighead, Ph.D.

202-962-6632


'/>"/>
SOURCE Gerson Lehrman Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gerson Lehrman Group Extends Partnership With BIO to Provide Scientific Expertise for the First Annual BIO National Venture Conference
2. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
3. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
4. China Pharma Holdings, Inc. Appoints The Ruth Group
5. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
6. iMedica Partners With LDM GROUP to Offer ScriptGuide to Physician Practice Customers
7. China Bio Energy Holdings Group Announces Financing and Exercise of Warrants
8. Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials
9. American Red Cross Expands Agreement for Strategic Blood Management(TM) Services from Strategic Healthcare Group LLC
10. Nyer Medical Group, Inc. Reports Revenues of $71.2 Million With Net Loss of $.10 Per Share for Fiscal Year 2008
11. AMERIGROUP Corporation to Discuss Third Quarter Earnings on October 23
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DIEGO and NEWARK, Del. ... , a privately-held regenerative medicine company, and W. ... materials science company, today announced a collaborative research agreement ... novel implantable cell therapy delivery device technologies that provide ... than a decade, ViaCyte has been developing innovative stem ...
(Date:3/29/2017)... /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") ... risk stratification test for breast cancer, via its ... BreastSentry incorporates a blood-based biomarker test with a sophisticated algorithm ... breast cancer.   ... BreastSentry measures the fasting plasma levels of two ...
(Date:3/29/2017)... The Global Microfluidic Chips Market by Manufacturers, ... and comprehensive study on the existing state of the global Microfluidic ... Europe and Asia-Pacific , ... and Africa . ... Browse 172 Tables and Figures, 13 Major Company ...
(Date:3/28/2017)... Hong Kong (PRWEB) , ... March 28, 2017 ... ... has selected NetDimensions Learning to replace paper-based processes and enhance training plan management ... “We are very pleased to partner with the SHL Group to help improve ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
(Date:3/2/2017)... Summary This report provides all the information ... partnering interests and activities since 2010. Download the ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
Breaking Biology News(10 mins):